SG11201901603RA - Methods of identifying epitopes - Google Patents
Methods of identifying epitopesInfo
- Publication number
- SG11201901603RA SG11201901603RA SG11201901603RA SG11201901603RA SG11201901603RA SG 11201901603R A SG11201901603R A SG 11201901603RA SG 11201901603R A SG11201901603R A SG 11201901603RA SG 11201901603R A SG11201901603R A SG 11201901603RA SG 11201901603R A SG11201901603R A SG 11201901603RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- methods
- protein
- pct
- epitopes
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000017854 proteolysis Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medical Informatics (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Library & Information Science (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614884.3A GB201614884D0 (en) | 2016-09-01 | 2016-09-01 | Method |
| PCT/EP2017/072001 WO2018042010A1 (en) | 2016-09-01 | 2017-09-01 | Methods of identifying epitopes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901603RA true SG11201901603RA (en) | 2019-03-28 |
Family
ID=57140094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901603RA SG11201901603RA (en) | 2016-09-01 | 2017-09-01 | Methods of identifying epitopes |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190194320A1 (es) |
| EP (1) | EP3507604A1 (es) |
| JP (3) | JP7032386B2 (es) |
| KR (1) | KR102441148B1 (es) |
| CN (1) | CN109791156B (es) |
| AU (1) | AU2017321032B2 (es) |
| BR (1) | BR112019004025A2 (es) |
| CA (1) | CA3035318A1 (es) |
| GB (1) | GB201614884D0 (es) |
| IL (1) | IL265123B1 (es) |
| MA (1) | MA46088A (es) |
| MX (1) | MX2019002455A (es) |
| NZ (1) | NZ752191A (es) |
| RU (1) | RU2771584C2 (es) |
| SG (1) | SG11201901603RA (es) |
| WO (1) | WO2018042010A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019178151A1 (en) * | 2018-03-13 | 2019-09-19 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2303264C2 (ru) * | 2001-02-19 | 2007-07-20 | Мерк Патент Гмбх | Способ идентификации эпитопов т-клеток и его применение для получения молекул со сниженной иммуногенностью |
| EP2364728A1 (en) * | 2003-07-15 | 2011-09-14 | Amgen, Inc | Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors |
| MA41842A (fr) * | 2015-03-31 | 2018-02-06 | Oblique Therapeutics Ab | Nouveaux procédés de sélection d'épitope |
-
2016
- 2016-09-01 GB GBGB1614884.3A patent/GB201614884D0/en not_active Ceased
-
2017
- 2017-09-01 BR BR112019004025A patent/BR112019004025A2/pt unknown
- 2017-09-01 EP EP17762093.7A patent/EP3507604A1/en active Pending
- 2017-09-01 MX MX2019002455A patent/MX2019002455A/es unknown
- 2017-09-01 MA MA046088A patent/MA46088A/fr unknown
- 2017-09-01 WO PCT/EP2017/072001 patent/WO2018042010A1/en unknown
- 2017-09-01 RU RU2019105088A patent/RU2771584C2/ru active
- 2017-09-01 KR KR1020197008877A patent/KR102441148B1/ko active IP Right Grant
- 2017-09-01 NZ NZ752191A patent/NZ752191A/en unknown
- 2017-09-01 CA CA3035318A patent/CA3035318A1/en active Pending
- 2017-09-01 JP JP2019511942A patent/JP7032386B2/ja active Active
- 2017-09-01 SG SG11201901603RA patent/SG11201901603RA/en unknown
- 2017-09-01 US US16/329,538 patent/US20190194320A1/en active Pending
- 2017-09-01 IL IL265123A patent/IL265123B1/en unknown
- 2017-09-01 AU AU2017321032A patent/AU2017321032B2/en active Active
- 2017-09-01 CN CN201780058673.4A patent/CN109791156B/zh active Active
-
2021
- 2021-11-29 JP JP2021193435A patent/JP2022033845A/ja active Pending
-
2023
- 2023-11-28 JP JP2023200922A patent/JP2024037751A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024037751A (ja) | 2024-03-19 |
| CN109791156B (zh) | 2022-11-22 |
| KR102441148B1 (ko) | 2022-09-06 |
| RU2019105088A3 (es) | 2020-12-21 |
| IL265123B1 (en) | 2024-04-01 |
| KR20190045252A (ko) | 2019-05-02 |
| MA46088A (fr) | 2019-07-10 |
| EP3507604A1 (en) | 2019-07-10 |
| AU2017321032B2 (en) | 2024-05-30 |
| AU2017321032A1 (en) | 2019-04-18 |
| BR112019004025A2 (pt) | 2019-08-20 |
| CN109791156A (zh) | 2019-05-21 |
| JP2022033845A (ja) | 2022-03-02 |
| WO2018042010A1 (en) | 2018-03-08 |
| JP2019536427A (ja) | 2019-12-19 |
| MX2019002455A (es) | 2019-05-30 |
| US20190194320A1 (en) | 2019-06-27 |
| CA3035318A1 (en) | 2018-03-08 |
| GB201614884D0 (en) | 2016-10-19 |
| NZ752191A (en) | 2023-03-31 |
| JP7032386B2 (ja) | 2022-03-08 |
| RU2019105088A (ru) | 2020-10-01 |
| IL265123A (es) | 2024-04-01 |
| RU2771584C2 (ru) | 2022-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
| SG11201906264YA (en) | Improved serum albumin binders | |
| SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
| SG11201903693QA (en) | Polypeptide variants and uses thereof | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201810149VA (en) | Anti hla-g specific antibodies | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201907422RA (en) | Anti-tau antibodies and methods of use thereof | |
| SG11201906961UA (en) | Polypeptide variants and uses thereof | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201908549RA (en) | Automated quality control and spectral error correction for sample analysis instruments | |
| SG11201806639VA (en) | New streptococcal proteases | |
| SG11201807794VA (en) | Naphthene-containing distillate stream compositions and uses thereof | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201809620UA (en) | The contorsbody - a single chain target binder | |
| SG11201803565UA (en) | Cd131 binding proteins and uses thereof | |
| SG11201903785TA (en) | Bivalent antibodies masked by coiled coils | |
| SG11201809473QA (en) | Humanized anti-basigin antibodies and the use thereof | |
| SG11201805497QA (en) | Mutated truncated von willebrand factor |